The company's proprietary platform provides respiratory support to patients with damaged lungs and acts as a temporary life support system by taking over the heart's function in case of acute heart failure, giving hospitals enough time to address underlying problems. Hemovent's goal is to redefine the field of Extracorporeal Life Support (ECLS and ECMO) by focusing on the essential requirements of patients and their treating physicians in critical situations where extracorporeal support is necessary.